Canadian OTC switch application inclusion of comparative label claims recommended in report.
This article was originally published in The Tan Sheet
Executive Summary
CANADIAN OTC SWITCH APPLICATION INCLUSION OF COMPARATIVE LABEL CLAIMS is suggested in a recent report on the Rx-to-OTC switch process issued for comment by the Canadian Drugs Directorate. The report, prepared for the directorate by Panacea Consulting Inc., recommends that the government's switch criteria "include submission of comparative therapeutic claims which will appear on the label, package and/or package insert" and that reviewers assess the information along with the rest of the submission.